Chromophobe renal cell carcinoma with sarcomatoid change. A case report.
Chromophobe renal cell carcinoma (RCC) is a newly established entity of renal neoplasm with histological and molecular biological features different from those of common RCCs. Chromophobe RCC shows characteristically cloudy and reticular cytoplasm and cellular features resembling distal nephron. Its prognosis has been reported to be more favorable than that of common RCCs. Recently, however, several cases have been reported which showed sarcomatoid change to present poor prognosis. Here we present a case of chromophobe RCC with sarcomatoid change which was once resected surgically. The surgically resected tumor was histologically composed of chromophobe epithelial cell sheets and sarcomatoid elements. The former showed positivity for colloid iron staining, and was immunohistochemically positive for E-cadherin and epithelial membrane antigen (EMA), whereas the latter was positive for vimentin instead of colloid iron and E-cadherin. EMA was focally positive in the sarcomatoid element. The patient died with systemic metastases 14 months after the operation. Histologically, the metastatic tumors were composed only of sarcomatoid element lacking epithelial element. Based on these findings and previous reports, this case supports the existence of a tumor progression pathway from chromophobe to sarcomatoid RCC. It is necessary to perform careful postoperative investigation of chromophobe RCC due to its possible histological progression to the sarcomatoid subtype.
Nagashima
Y
Y
Department of Pathology, Yokohama City University School of Medicine, Yokohama, Japan. ynagas@med.yokohama-cu.ac.jp
Okudela
K
K
Osawa
A
A
Nakamura
N
N
Kawasaki
C
C
Moriyama
M
M
Nakamura
N
N
Nakatani
Y
Y
Kitamura
H
H
Aoki
I
I
D000230:Adenocarcinoma / Q000737:chemistry / Q000473:pathology* / Q000628:therapy; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D015820:Cadherins / Q000032:analysis; D002292:Carcinoma, Renal Cell / Q000737:chemistry / Q000473:pathology* / Q000628:therapy; D003102:Colloids; D004396:Coloring Agents; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D006878:Hydroxides; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000737:chemistry / Q000473:pathology* / Q000628:therapy; D018396:Mucin-1 / Q000032:analysis; D009378:Neoplasms, Multiple Primary / Q000737:chemistry / Q000473:pathology* / Q000628:therapy; D009392:Nephrectomy; D009930:Organic Chemicals; D012509:Sarcoma / Q000737:chemistry / Q000473:pathology* / Q000628:therapy; D013194:Staining and Labeling; D014750:Vincristine / Q000008:administration & dosage
D015820:Cadherins; D003102:Colloids; D004396:Coloring Agents; D006878:Hydroxides; D018396:Mucin-1; D009930:Organic Chemicals; C083971:colloidal iron hydroxide; D014750:Vincristine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide